Bertin Technologies SAS
Bertin Technologies SAS
06/15/2026 | News release | Distributed by Public on 06/15/2026 09:15
Cayman, Pioneer in Lipid Nanoparticle Research
Cayman, Pioneer in Lipid Nanoparticle Research
15 Jun 2026
Lipid nanoparticles (LNPs) now occupy a central role in the development of innovative nucleic acid-based therapies. Used as vectors to deliver therapeutic molecules into cells, they represent a key driver across fields as varied as vaccination, oncology and gene therapy. Their development nonetheless remains a demanding process, requiring specialist expertise and significant resources.
Drawing on over 45 years of expertise in lipid research, Cayman has developed the LipidLaunch™ range to meet the practical needs of research teams. Comprising ready-to-use LNPs and reagent kits, this range has been designed to simplify formulation stages and provide researchers with reliable, reproducible and immediately operational tools.
LipidLaunch™ enables teams to save valuable time and focus their efforts on analysis, discovery and the development of new therapies. As an official distributor of Cayman products in France, Bertin Bioreagent makes this range available to support the most ambitious research projects.
Bertin Technologies SAS published this content on June 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 15, 2026 at 15:15 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]